ロード中...
A randomized phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer
BACKGROUND: Olaparib is an oral poly(ADP-ribose) polymerase inhibitor and cediranib is an oral anti-angiogenic with activity against VEGFR-1, 2, and 3. Both agents have antitumor activity in women with recurrent ovarian cancer, and the combination of these agents was active and had manageable toxici...
保存先:
| 出版年: | Lancet Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2014
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4294183/ https://ncbi.nlm.nih.gov/pubmed/25218906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70391-2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|